This trial is active, not recruiting.

Condition prostate cancer
Treatment iodine i 125
Sponsor Translational Research Informatics Center, Kobe, Hyogo, Japan
Start date July 2005
End date December 2015
Trial size 7000 participants
Trial identifier NCT00534196, CDR0000562726, TUSM-BRI-GU-04-01


RATIONALE: Implant radiation therapy delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This clinical trial is studying the side effects and how well implant radiation therapy using radioactive iodine works in treating patients with localized prostate cancer.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Primary purpose treatment

Primary Outcomes

PSA relapse-free survival
time frame:

Secondary Outcomes

time frame:
Quality of life
time frame:
IPSS score
time frame:

Eligibility Criteria

Male participants of any age.

DISEASE CHARACTERISTICS: - Clinically and histologically confirmed localized prostate cancer PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - No prior or concurrent surgery - No prior or concurrent radiotherapy - Prior chemotherapy, hormonal therapy, and biologic therapy allowed

Additional Information

Official title Japanese Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation [J-POPS]
Description OBJECTIVES: - To determine the efficacy of permanent brachytherapy with iodine I 125 seeds in patients with localized prostate cancer. - To determine the safety of this therapy in these patients. OUTLINE: This is a multicenter study. Patients undergo permanent brachytherapy seed implantation comprised of iodine I 125 into the prostate. Some patients may receive combination treatment (e.g., external beam radiation therapy (EBRT) or hormone therapy in addition to brachytherapy). Quality of life and the International Prostate Symptom Score (IPSS) is assessed and compared.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).